Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits
SAN DIEGO, CA--(Marketwired - Jan 31, 2017) - Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular diagnostics®, today …